Prelude Therapeutics (PRLD) Free Cash Flow (2019 - 2026)
Prelude Therapeutics (PRLD) reported Free Cash Flow of -$21.7 million for Q1 2026, up 36.74% on a YoY basis from -$15.9 million in Q1 2025, and down 193.8% sequentially from $23.1 million in Q4 2025.
Prelude Therapeutics (PRLD) Free Cash Flow (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Free Cash Flow data on file, last reported at -$21.7 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 36.74% year-over-year to -$21.7 million; the trailing twelve-month figure through Mar 2026 stood at -$43.8 million (up 58.35% YoY), and the FY2025 full-year result was -$56.4 million, up 45.22% from the prior year.
- Free Cash Flow eased to -$21.7 million in Q1 2026, from $23.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $23.1 million in Q4 2025 to a low of -$34.3 million in Q1 2025.
- A 5-year average of -$22.1 million and a median of -$23.4 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 44.53% in 2023 and soared 215.35% in 2025, its largest moves.
- Tracing PRLD's Free Cash Flow over 5 years: stood at -$22.7 million in 2022, then decreased by 8.87% to -$24.7 million in 2023, then increased by 18.88% to -$20.0 million in 2024, then soared by 215.35% to $23.1 million in 2025, then slumped by 193.8% to -$21.7 million in 2026.
- Business Quant data shows PRLD's Free Cash Flow at -$21.7 million in Q1 2026, $23.1 million in Q4 2025, and -$19.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -21.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.69 Mn |
| Mar 31, 2026 | -21.69 Mn |
| Dec 31, 2025 | 23.12 Mn |
| Dec 31, 2025 | 23.12 Mn |
| Sep 30, 2025 | -19.12 Mn |
| Sep 30, 2025 | -19.12 Mn |
| Jun 30, 2025 | -26.10 Mn |
| Jun 30, 2025 | -26.10 Mn |
| Mar 31, 2025 | -34.28 Mn |
| Mar 31, 2025 | -34.28 Mn |
| Dec 31, 2024 | -20.04 Mn |
| Dec 31, 2024 | -20.04 Mn |
| Sep 30, 2024 | -27.36 Mn |
| Sep 30, 2024 | -27.36 Mn |
| Jun 30, 2024 | -23.42 Mn |
| Jun 30, 2024 | -23.42 Mn |
| Mar 31, 2024 | -32.08 Mn |
| Mar 31, 2024 | -32.08 Mn |
| Dec 31, 2023 | -24.71 Mn |
| Dec 31, 2023 | -24.71 Mn |